Switch theme
Sign up to access all valuation multiples
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
2017
22
Last FY Revenue n/a
LTM EBITDA -$23.0M
$96.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cardiol Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$23.0M.
In the most recent fiscal year, Cardiol Therapeutics achieved revenue of n/a and an EBITDA of -$39.9M.
Cardiol Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cardiol Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$23.0M | XXX | -$39.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$29.0M | XXX | -$40.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$28.0M | XXX | -$36.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Cardiol Therapeutics's stock price is $1.
Cardiol Therapeutics has current market cap of $110M, and EV of $96.8M.
See Cardiol Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $96.8M | $110M | XXX | XXX | XXX | XXX | $-0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Cardiol Therapeutics has market cap of $110M and EV of $96.8M.
Cardiol Therapeutics's trades at n/a EV/Revenue multiple, and -2.4x EV/EBITDA.
Equity research analysts estimate Cardiol Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cardiol Therapeutics has a P/E ratio of -3.9x.
See valuation multiples for Cardiol Therapeutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV (current) | $96.8M | XXX | $96.8M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -4.2x | XXX | -2.4x | XXX | XXX | XXX |
| EV/EBIT | -3.3x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.9x | XXX | -3.0x | XXX | XXX | XXX |
| EV/FCF | -5.8x | XXX | -3.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCardiol Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.8M for the same period.
Cardiol Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cardiol Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cardiol Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cardiol Therapeutics acquired XXX companies to date.
Last acquisition by Cardiol Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cardiol Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Cardiol Therapeutics founded? | Cardiol Therapeutics was founded in 2017. |
| Where is Cardiol Therapeutics headquartered? | Cardiol Therapeutics is headquartered in United States of America. |
| How many employees does Cardiol Therapeutics have? | As of today, Cardiol Therapeutics has 22 employees. |
| Who is the CEO of Cardiol Therapeutics? | Cardiol Therapeutics's CEO is Mr. David G. Elsley, M.B.A.. |
| Is Cardiol Therapeutics publicy listed? | Yes, Cardiol Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cardiol Therapeutics? | Cardiol Therapeutics trades under CRDL ticker. |
| When did Cardiol Therapeutics go public? | Cardiol Therapeutics went public in 2019. |
| Who are competitors of Cardiol Therapeutics? | Similar companies to Cardiol Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Cardiol Therapeutics? | Cardiol Therapeutics's current market cap is $110M |
| Is Cardiol Therapeutics profitable? | Yes, Cardiol Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cardiol Therapeutics? | Cardiol Therapeutics's last 12 months EBITDA is -$23.0M. |
| What is the current EV/EBITDA multiple of Cardiol Therapeutics? | Current EBITDA multiple of Cardiol Therapeutics is -4.2x. |
| What is the current FCF of Cardiol Therapeutics? | Cardiol Therapeutics's last 12 months FCF is -$16.8M. |
| What is the current EV/FCF multiple of Cardiol Therapeutics? | Current FCF multiple of Cardiol Therapeutics is -5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
